TABLE 3.

Clinical-Molecular Association Analysis: The five relevant molecules, associated with incomplete anti-VEGF response, were explored for potential associations with clinical parameters, in all neovascular age-related macular degeneration (nAMD) eyes included. Correlation analysis was performed for continuous variable, and Anova test for categorical variables.

	sVCAM-1		IL-12p40		IL-6		PAI-1		HGF		VEGF-A
Continuous variables	r2	p	r2	p	r2	p	r2	p	r2	p	r2	p
Age	0.20	0.22	0.32	0.05	0.17	0.29	0.24	0.13	0.38	0.01	0.07	0.67
N anti-VEGF injections	0.26	0.10	0.30	0.06	0.26	0.11	0.13	0.42	0.26	0.10	0.13	0.42
N months of treatment	0.14	0.40	0.21	0.19	0.25	0.10	0.08	0.60	0.15	0.35	0.09	0.60
VA change from baseline	0.18	0.25	0.01	0.93	−0.35	0.03	0.16	0.32	0.18	0.27	−0.11	0.47
Central retinal thickness	0.19	0.24	0.29	0.07	0.04	0.80	0.26	0.12	0.18	0.26	0.04	0.82
Subfoveal choroidal thickness	−0.40	0.01	−0.46	0.003	−0.27	0.10	−0.26	0.10	−0.44	0.005	−0.14	0.38
Categorical variables	p		p		p		p		p		p
Reticular pseudodrusen	0.38		0.69		0.36		0.56		0.86		0.58
Intraretinal fluid	0.74		0.87		0.22		0.41		0.8		0.55
Subretinal fluid	0.73		0.4		0.42		0.99		0.93		0.69
cRORA	0.83		0.7		0.36		0.36		0.7		0.51
iRORA	0.97		0.61		0.42		0.89		0.71		0.65
CNV type	0.1		0.62		0.83		0.005		0.36		0.38
Fibrosis	0.95		0.92		0.66		0.5		0.99		0.5

cRORA, complete retinal pigment epithelium pigment and outer retinal atrophy; iRORA, incomplete retinal pigment epithelium pigment and outer retinal atrophy. Significant values are showed in bold.